Literature DB >> 29535909

Transcriptional deregulation underlying the pathogenesis of small cell lung cancer.

Dong-Wook Kim1, Keun-Cheol Kim1,2, Kee-Beom Kim1, Colin T Dunn1, Kwon-Sik Park1.   

Abstract

The discovery of recurrent alterations in genes encoding transcription regulators and chromatin modifiers is one of the most important recent developments in the study of the small cell lung cancer (SCLC) genome. With advances in models and analytical methods, the field of SCLC biology has seen remarkable progress in understanding the deregulated transcription networks linked to the tumor development and malignant progression. This review will discuss recent discoveries on the roles of RB and P53 family of tumor suppressors and MYC family of oncogenes in tumor initiation and development. It will also describe the roles of lineage-specific factors in neuroendocrine (NE) cell differentiation and homeostasis and the roles of epigenetic alterations driven by changes in NFIB and chromatin modifiers in malignant progression and chemoresistance. These recent findings have led to a model of transcriptional network in which multiple pathways converge on regulatory regions of crucial genes linked to tumor development. Validation of this model and characterization of target genes will provide critical insights into the biology of SCLC and novel strategies for tumor intervention.

Entities:  

Keywords:  chromatin modifier; genetically engineered mouse model (GEMM); small cell lung cancer (SCLC); transcription factor

Year:  2018        PMID: 29535909      PMCID: PMC5835594          DOI: 10.21037/tlcr.2017.10.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  180 in total

1.  Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

Authors:  Serdar Arisan; Elif Damla Buyuktuncer; Narcin Palavan-Unsal; Turhan Caşkurlu; Omer Onur Cakir; Erbil Ergenekon
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

2.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

Authors:  Philip Kahl; Lucia Gullotti; Lukas Carl Heukamp; Susanne Wolf; Nicolaus Friedrichs; Roland Vorreuther; Gerold Solleder; Patrick J Bastian; Jörg Ellinger; Eric Metzger; Roland Schüle; Reinhard Buettner
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

3.  Nuclear factor I/B is an oncogene in small cell lung cancer.

Authors:  Alison L Dooley; Monte M Winslow; Derek Y Chiang; Shantanu Banerji; Nicolas Stransky; Talya L Dayton; Eric L Snyder; Stephanie Senna; Charles A Whittaker; Roderick T Bronson; Denise Crowley; Jordi Barretina; Levi Garraway; Matthew Meyerson; Tyler Jacks
Journal:  Genes Dev       Date:  2011-07-15       Impact factor: 11.361

4.  Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.

Authors:  L Zhu; S van den Heuvel; K Helin; A Fattaey; M Ewen; D Livingston; N Dyson; E Harlow
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

5.  A novel human insulinoma-associated cDNA, IA-1, encodes a protein with "zinc-finger" DNA-binding motifs.

Authors:  Y Goto; M G De Silva; A Toscani; B S Prabhakar; A L Notkins; M S Lan
Journal:  J Biol Chem       Date:  1992-07-25       Impact factor: 5.157

6.  MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

Authors:  B E Johnson; E Russell; A M Simmons; R Phelps; S M Steinberg; D C Ihde; A F Gazdar
Journal:  J Cell Biochem Suppl       Date:  1996

7.  L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.

Authors:  M M Nau; B J Brooks; J Battey; E Sausville; A F Gazdar; I R Kirsch; O W McBride; V Bertness; G F Hollis; J D Minna
Journal:  Nature       Date:  1985 Nov 7-13       Impact factor: 49.962

8.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

9.  Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer.

Authors:  Tangfeng Lv; Dongmei Yuan; Xiaohui Miao; Yanling Lv; Ping Zhan; Xiaokun Shen; Yong Song
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

10.  Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast.

Authors:  Nuran Serce; Annette Gnatzy; Susanne Steiner; Henning Lorenzen; Jutta Kirfel; Reinhard Buettner
Journal:  BMC Clin Pathol       Date:  2012-08-24
View more
  6 in total

Review 1.  Signal pathways and precision therapy of small-cell lung cancer.

Authors:  Min Yuan; Yu Zhao; Hendrik-Tobias Arkenau; Tongnei Lao; Li Chu; Qing Xu
Journal:  Signal Transduct Target Ther       Date:  2022-06-15

2.  Novel evidence for retinoic acid-induced G (Rig-G) as a tumor suppressor by activating p53 signaling pathway in lung cancer.

Authors:  Junjun Sun; Xuan Wang; Wenfang Liu; Ping Ji; Anquan Shang; Junlu Wu; Hao Zhou; Wenqiang Quan; Yiwen Yao; Yibao Yang; ChenZheng Gu; Zujun Sun; Ajay Goel; Wenhao Weng; Dong Li
Journal:  FASEB J       Date:  2020-08-02       Impact factor: 5.191

3.  Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.

Authors:  Mingrui Zhu; Yi Huang; Matthew E Bender; Luc Girard; Rahul Kollipara; Buse Eglenen-Polat; Yujiro Naito; Trisha K Savage; Kenneth E Huffman; Shohei Koyama; Atsushi Kumanogoh; John D Minna; Jane E Johnson; Esra A Akbay
Journal:  Cancer Res       Date:  2021-01-25       Impact factor: 13.312

Review 4.  Molecular profiles of small cell lung cancer subtypes: therapeutic implications.

Authors:  Anna Schwendenwein; Zsolt Megyesfalvi; Nandor Barany; Zsuzsanna Valko; Edina Bugyik; Christian Lang; Bence Ferencz; Sandor Paku; Andras Lantos; Janos Fillinger; Melinda Rezeli; Gyorgy Marko-Varga; Krisztina Bogos; Gabriella Galffy; Ferenc Renyi-Vamos; Mir Alireza Hoda; Walter Klepetko; Konrad Hoetzenecker; Viktoria Laszlo; Balazs Dome
Journal:  Mol Ther Oncolytics       Date:  2021-02-06       Impact factor: 7.200

5.  Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.

Authors:  Federico Costanzo; Marta Martínez Diez; Gema Santamaría Nuñez; Juan Ignacio Díaz-Hernandéz; Carlos Mario Genes Robles; Javier Díez Pérez; Emmanuel Compe; Romeo Ricci; Tsai-Kun Li; Frédéric Coin; Juan Fernando Martínez Leal; Eva Maria Garrido-Martin; Jean Marc Egly
Journal:  EMBO Mol Med       Date:  2022-03-09       Impact factor: 12.137

6.  MicroRNA-497-5p negatively regulates the proliferation and cisplatin resistance of non-small cell lung cancer cells by targeting YAP1 and TEAD1.

Authors:  Shang-Gan Zeng; Jian-Hong Xie; Qun-Ying Zeng; Shao-Hua Dai; Yun Wang; Xue-Mei Wan; Xue-Liang Zhou
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.